Each entry includes mechanism, evidence summary, FDA / regulatory status, safety profile and 2026 update. Organized by therapeutic category.
Selective ghrelin receptor agonist · stimulates GH without prolactin/cortisol increase
Not FDA-approved · InvestigatiLong-acting GHRH analog · pairs with ipamorelin for sustained GH release
Not FDA-approved · InvestigatiOriginal ghrelin mimetic · stimulates GH and appetite
The most-studied GLP-1 agonist · FDA-approved for type 2 diabetes and obesity
FDA-approved · Mounjaro (T2D)Dual GLP-1 + GIP receptor agonist · most effective weight-loss peptide approved
Not FDA-approved · Investigati16-amino-acid mitochondrial peptide · metabolic regulator